33 Another mechanism of bacterial drug resistance is reduced permeability, which prevents the entry of drugs
doi: 10.1038/nature15541 62 KhandiaR.DadarM.MunjalA.DhamaK.KarthikK.TiwariR.et al
doi: 10.1042/ebc20180038 96 PatrickGL
Key Specs Research context: NNMT interaction, enzyme and pathway assays Common model types: biochemical assays, cell-based pathway studies References: PubChem and PubMed [1,2] Referenced Citations PubChem, 5-Amino-1-methylquinolinium: PubMed, NNMT and metabolic regulation (review and mechanistic context): NNMT Interaction Studies 5-AMINO-1MQ is primarily examined for its inhibitory interaction with NNMT, an enzyme involved in nicotinamide methylation and NAD-related metabolism [1,2]
What the FDA will review (and when) According to the FDA Law Blog breakdown, the FDA has scheduled the Pharmacy Compounding Advisory Committee (PCAC) to review peptides for possible inclusion on the Section 503A bulks list on two timelines: PCAC meeting: July 2324, 2026 July 23: BPC-157, KPV, TB-500, MOTs-C (FDA Law Blog) July 24: Emideltide (DSIP), Semax, Epithalon (FDA Law Blog) Second PCAC meeting: before the end of February 2027 GHK-Cu, Melanotan II, Cathelicidin (LL-37), Dihexa acetate, PEG-MGF (FDA Law Blog) Well update this post as the FDA releases briefing packets, conflict-of-interest disclosures, and voting questions closer to the meeting
Interestingly, the incubation with the antioxidant N-acetylcysteine (NAC) upon treatment with NP4 resulted in reduced levels of apoptosis, suggestive that the cytotoxicity of NP4 is related to intracellular redox homeostasis (Supplementary Fig
